GSK PLC Sponsored ADR (NYSE:GSK) Given Average Recommendation of “Hold” by Analysts

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have earned a consensus rating of “Hold” from the ten analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $53.00.

A number of brokerages have recently issued reports on GSK. HSBC raised GSK from a “reduce” rating to a “hold” rating in a research report on Monday, July 6th. Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a research note on Tuesday, June 9th. Wall Street Zen upgraded GSK from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research report on Thursday. Finally, Weiss Ratings downgraded shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 11th.

Institutional Investors Weigh In On GSK

Several hedge funds and other institutional investors have recently modified their holdings of GSK. First Horizon Corp raised its stake in shares of GSK by 78.7% in the 4th quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 236 shares in the last quarter. Elyxium Wealth LLC bought a new stake in GSK in the fourth quarter valued at about $30,000. Triumph Capital Management bought a new stake in GSK in the third quarter valued at about $40,000. 1248 Management LLC raised its stake in GSK by 314.6% during the third quarter. 1248 Management LLC now owns 1,053 shares of the pharmaceutical company’s stock valued at $46,000 after buying an additional 799 shares in the last quarter. Finally, Coston McIsaac & Partners raised its stake in GSK by 17.3% during the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock valued at $68,000 after buying an additional 206 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Up 0.6%

GSK stock traded up $0.30 during trading on Friday, reaching $52.77. The stock had a trading volume of 2,867,656 shares, compared to its average volume of 3,280,796. GSK has a 1-year low of $35.45 and a 1-year high of $61.69. The company has a current ratio of 0.79, a quick ratio of 0.52 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $106.87 billion, a P/E ratio of 13.71, a PEG ratio of 3.39 and a beta of 0.35. The firm has a fifty day moving average price of $51.44 and a 200 day moving average price of $53.23.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 9th. Shareholders of record on Friday, May 15th were paid a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date was Friday, May 15th. GSK’s dividend payout ratio is 46.49%.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.